Efficacy of Peptide Receptor Radionuclide Therapy in Patients with Advanced Bronchial Neuroendocrine Tumours Abstract #1416

Introduction: There is not established treatment pathway in advanced bronchial neuroendocrine tumours(bNETs).
Aim(s): To assess efficacy of Peptide Receptor Radionuclide Therapy(PRRT) on bNETs.
Materials and methods: A retrospective analysis included 22 patients with bNETs,progressing despite previous treatment,who received PRRT.Symptomatic improvement,biochemical improvement[>50% decrease in Chromogranin A levels],time to disease progression(TTP) and renal and bone marrow toxicity(WHO criteria) were assessed.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Apostolos Koffas
Keywords: PRRT, bronchial NETs

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1363 Efficacy of Lutetium-177 DOTA Octreotate Peptide Receptor Radionuclide Therapy in Patients with Advanced Neuroendocrine Tumours and Carcinoid Syndrome Refractory to Somatostatin Analogues
Introduction: Somatostatin Analogues (SSAs) are considered the gold standard treatment in Neuroendocrine Tumours (NETs) and carcinoid syndrome.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Apostolos Koffas
#1814 Predictors of Outcome in Patients Treated with Peptide Radio-Labelled Receptor Target Therapy (PRRT)
Introduction: The efficacy of PRRT has been demonstrated in patients with well differentiated NETS. The NETTER-01 study demonstrated disease stabilisation or partial response in approximately 80% of patients. However, more studies are needed to identify predictors of response
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Georgios Demetriou
Keywords: PRRT, Y90, Lu-177
#2292 PFS and OS after Salvage Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors (GEP-NETs) – The Rotterdam Cohort
Introduction: PRRT with 177Lu-DOTATATE (LuTate) is effective in patients with metastatic or inoperable GEP-NETs.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Wouter van der Zwan
#2187 Typical and Atypical Bronchial NETs with Advanced Disease: Incidence, Management and Survival
Introduction: Bronchial NETs are classified according to the 2004 WHO classification into typical, atypical and poorly differentiated. Typical and atypical tumours can develop metastatic disease (Stage IV) which requires careful management
Conference: 15th Annual ENETS conference (2018)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Dr Dalvinder Mandair
#1228 Measurement of Blood Gene Transcripts Defines PRRT Therapeutic Efficacy
Introduction: PRRT is an effective therapy for NETs since the majority over-express SSRs. Typically, well or moderately differentiated NETs (G1/G2) are treated. Imaging and CgA are used to evaluate response but both RECIST criteria and CgA have limitations.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Bodei L, Paganelli G, Kidd M, Severi S, ...
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team